Providing Guidance and Support for all KPNW Research Compliance Activities


Your Feedback Requested!

Help the Research Compliance team by completing an anonymous survey about your experience with the Research Compliance Department's customer service.  We appreciate your input!

Click here to access the survey.

Next IRB meeting: June 21, 2017

Submissions for review at the June 2017 IRB meeting should be submitted through the electronic IRB system (eIRB) by the end of work on 6/1/2017.

RE: Continuing Review Submissions: It is the Principal Investigator's responsibility to submit a report for continuing review by the submission deadline.

The eIRB sends courtesy reminders to the study team when a continuing review submission is due. Reminders are sent at 90, 60, and 30 days prior to the approval expiration date. These are the only reminders the study team will receive.

Reminders are discontinued after a continuing form has been opened. If you create a continuing review in the eIRB when you receive the 90-day reminder, you will not receive additional reminders at 60 and 30 days.

Welcome Kaiser Permanente Washington!

Group Health is now Kaiser Permanente Washington. The eIRB system has been updated to reflect this change. Remember to search for "Kaiser Permanente Washington IRB" on the picklist when submitting a request for KPNW to rely on the KP Washington IRB for review of a study. All references in new study applications should be to KP Washington.

Updating Existing Studies Conducting Collaborative Research with KP Washington

Study teams should update references to Group Health in the application form with the next submission to modify the study. If the next submission is for contining review, submit a combined modification and continuing review. It is not necessary to submit a study modification solely to make the update.

For existing studies ceded to Group Health, the eIRB automatically updated the name in the External IRB section of the application.

Data or Specimen Sharing Agreements with KP Washington

Please use the full KP DUA, DTA, or MDTA templates when developing new sharing agreements with KP Washington.


The upgraded eIRB system went live on June 2, 2016.

Existing studies in the approved, ceded, or exempt status were migrated to the new system on June 1 unless they had an open modification or continuing review. Studies with open submissions (new study, modification, continuing review, reportable event) in the old system will be migrated to the new system after IRB approval. Study staff will be able to access the study in the new system the following day.

On the first submission after migration:

  • Read the blue text at the top of the mod/CR form!
  • Update study personnel
  • Move documents from the old system
  • Check that migrated information is correct
  • Fill in missing information

If the first submission for a migrated study is a final report, you will not need to make any other updates to study information.

For more guidance: eIRB Upgrade Info Sheet

If you have any questions, please contact us.


Compliance Committee Meeting Schedule

  • CHR Research Compliance Committee (local/NW) meets the second Wed of the month.
  • Hawaii CHR representatives join the committee on a quarterly basis.

View 2017 RCC Charter & Membership


Designed to enable researchers and IRB reviewers to manage all aspects of the Institutional Review Board (IRB) Administration process.

Enter the eIRB

About the eIRB

eIRB Training

Research Compliance Newsletter

Winter 2017 Newsletter Archive

For IRB Members

Find information and documentation to support the following tasks:

Study Reviews

IRB Member Orientation

About Research Compliance & IRB

The Research Subjects Protection Office (RSPO) is an administrative office for the Institutional Review Board (IRB) at Kaiser Permanente Northwest (KPNW).

Learn More

Resources & References

Find useful information about ethical principles, federal regulations, genetic research, informed consent readability and more.


Policies & Procedures

Find vital information about Financial Conflicts of Interest, FDA-Regulated Clinical Trials, Privacy Policies, Research Integrity, Security, and Human Research Protection.